Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?

Author information

Affiliations

  • 1. Memorial Sloan-Kettering Cancer Center, New York, NY 10022, USA.
      Authors
    • Abou-Alfa GK 1
    (1 author)

The Oncologist, 14 Jan 2009, 14(1):92-94
https://doi.org/10.1634/theoncologist.2008-0294 PMID: 19144679 

This is a comment on "Sorafenib for the treatment of unresectable hepatocellular carcinoma." Oncologist. 2009 Jan;14(1):95-100.

Abstract 

No abstract provided.

Full text links 

Read article at publisher's site: https://doi.org/10.1634/theoncologist.2008-0294

Read article for free, from open access legal sources, via Unpaywall: http://theoncologist.alphamedpress.org/content/14/1/92.full.pdfUnpaywall

Free to read at intl-theoncologist.alphamedpress.org
http://intl-theoncologist.alphamedpress.org/cgi/content/abstract/14/1/92

Free to read at intl-theoncologist.alphamedpress.org
http://intl-theoncologist.alphamedpress.org/cgi/content/full/14/1/92

Citations & impact 

Impact metrics

7
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (7) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.